Method for optimizing thiopurine efficacy and toxicity using mass spectrometry
AssigneePrometheus Laboratories Inc.
InventorThierry Dervieux
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for optimizing therapeutic efficacy or reducing toxicity in a subject receiving a drug providing 6-thioguanine nucleotide. The methods provide determining 6-thioguanine and 6-methyl-mercaptopurine nucleotide concentration levels using an analytical technique having an ionizing source.
Claims43
A method for optimizing therapeutic efficacy in a subject receiving a drug providing 6-thioguanine nucleotide, said method comprising:
- (a) determining a concentration level of 6-thioguanine nucleotide (6-TGN) in said subject using an analytical technique having an ionizing source;
- and
- (b) increasing the subsequent dose of said drug when said concentration level of 6-thioguanine nucleotide is less than a predetermined efficacy value.
A method for reducing toxicity in a subject receiving a drug providing 6-thioguanine nucleotide (6-TGN), said method comprising:
- (a) determining a concentration level of 6-thioguanine nucleotide (6-TGN) in said subject using an analytical technique having an ionizing source;
- and
- (b) decreasing the subsequent dose of said drug when said concentration level of 6-thioguanine is greater than a predetermined toxicity value.
A method for reducing toxicity in a subject receiving a drug providing 6-thioguanine nucleotide, said method comprising:
- (a) determining a concentration level of 6-methyl-mercaptopurine nucleotide (6-MMPN) in said subject using an analytical technique having an ionizing source;
- and
- (b) decreasing the subsequent dose of said drug when said concentration level of 6-methyl-mercaptopurine nucleotide (6-MMPN) is greater than 6-methyl-mercaptopurine toxicity value.
A method for optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, said method comprising:
- determining a concentration level using an analytical technique having an ionizing source of 6-thioguanine nucleotide (6-TGN) or 6-methyl-mercaptopurine nucleotide (6-MMPN) in a subject administered a drug providing 6-thioguanine nucleotide, said subject having said immune-mediated gastrointestinal disorder,
- wherein a concentration level of 6-thioguanine nucleotide (6-TGN) less than a predetermined efficacy value indicates a need to increase the amount of said drug subsequently administered to said subject, and
- wherein a concentration level of 6-thioguanine nucleotide (6-TGN) greater than a predetermined toxicity level or a concentration level of 6-methyl-mercaptopurine nucleotide (6-MMPN) greater than a predetermined 6-MMPN toxicity level indicates a need to decrease the amount of said drug subsequently administered to said subject.
A method for optimizing therapeutic efficacy or reducing toxicity in a subject receiving a drug providing 6-thioguanine nucleotide, the method comprising:
- (a) determining a concentration level of 6-thioguanine nucleotide (6-TGN) in the subject using an analytical technique having an ionizing source;
- and
- (b) recommending a subsequent dose of the drug when said concentration level of 6-thioguanine nucleotide is compared to a predetermined value.
A method for communicating to an individual a subsequent dose of a drug providing 6-thioguanine nucleotide in a subject, said method comprising:
- (a) determining a concentration level of 6-thioguanine nucleotide (6-TGN) in the subject using an analytical technique having an ionizing source;
- and
- (b) communicating to said individual said subsequent dose via a computer-generated medium.
Dependencies are inferred from the claim text.